esopram filmuhúðuð tafla 15 mg
teva b.v.* - escitalopramum oxalat - filmuhúðuð tafla - 15 mg
esopram filmuhúðuð tafla 20 mg
teva b.v.* - escitalopramum oxalat - filmuhúðuð tafla - 20 mg
esopram filmuhúðuð tafla 5 mg
teva b.v.* - escitalopramum oxalat - filmuhúðuð tafla - 5 mg
oropram filmuhúðuð tafla 10 mg
teva b.v.* - citalopram hydrobromide - filmuhúðuð tafla - 10 mg
oropram filmuhúðuð tafla 20 mg
teva b.v.* - citalopram hydrobromide - filmuhúðuð tafla - 20 mg
oropram filmuhúðuð tafla 40 mg
teva b.v.* - citalopram hydrobromide - filmuhúðuð tafla - 40 mg
sotalol viatris (sotalol mylan) tafla 40 mg
viatris limited - sotalolum hýdróklóríð - tafla - 40 mg
sotalol viatris (sotalol mylan) tafla 80 mg
viatris limited - sotalolum hýdróklóríð - tafla - 80 mg
camzyos
bristol-myers squibb pharma eeig - mavacamten - cardiomyopathy, hypertrophic - Önnur hjartablöndur - treatment of symptomatic obstructive hypertrophic cardiomyopathy.
cabometyx
ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - Æxlishemjandi lyf - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.